A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients

Inclusion Criteria: * Screening serum uric acid level ≥ 8 mg/dL; * Body weight ≥ 50 kg and a body mass index (BMI) ≥ 18 and ≤ 40 kg/m2; * Free of any clinically significant disease or medical condition, per the Investigator's judgment. Exclusion Criteria: * History or suspicion of kidney stones; * Diagnosis of benign prostatic hypertrophy (BPH) or neurogenic bladder or evidence of BPH/neurogenic bladder such as thin urinary stream or difficulty in urination; * An estimated creatinine clearance \< 60 mL/min calculated by the Cockcroft-Gault formula; * QTcF interval (QT interval corrected for heart rate using Fridericia's formula) \> 450 msec at Screening; * Receiving strong or moderate Cytochrome P450 (CYP) 3A inhibitors or p-glycoprotein inhibitors, or digoxin